Open AccessHTX-011 effectively reduces postoperative pain intensity and opioid use in the elderly
Author(s) -
Tina Yip,
Jia Hu,
Pamela S Hawn,
Amy Yamamoto,
Gary M. Oderda
Publication year - 2022
Publication title -
pain management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.402
H-Index - 21
eISSN - 1758-1877
pISSN - 1758-1869
DOI - 10.2217/pmt-2021-0043
Subject(s) - medicine , bupivacaine , anesthesia , placebo , opioid , local anesthetic , surgery , receptor , alternative medicine , pathology
Aim: HTX-011 (ZYNRELEF™) is an extended-release, dual-acting local anesthetic containing bupivacaine and meloxicam. In bunionectomy and herniorrhaphy studies, HTX-011 resulted in less postoperative pain and less opioid consumption versus bupivacaine HCl. Here we evaluate HTX-011 in patients aged ≥65 years. Materials & methods: Patients received placebo, bupivacaine HCl or HTX-011 following surgery. End points included pain intensity, total opioid consumption, opioid-free patients and safety. Results: HTX-011-treated patients reported lower postoperative pain through 72 h versus bupivacaine HCl and placebo. Elderly patients administered HTX-011 used fewer opioids versus bupivacaine HCl, and a greater proportion remained opioid-free through 72 h. HTX-011 was well tolerated with a safety profile similar to bupivacaine HCl and placebo. Conclusion: HTX-011 maintained effectiveness and was well tolerated in elderly patients. Clinical Trial registration numbers: NCT03295721 and NCT03237481